Momenta Phamaceuticals, Inc. (MNTA) Tops Q1 EPS by 2c; Updates FY14 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Momenta Phamaceuticals, Inc. (MNTA) Enters $75M At-The-Market Sales Agreement
May 6, 2014 8:26 AM EDTOn May 6, 2014, Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) entered into an At-The-Market Equity Offering Sales Agreement (the Sales Agreement) with Stifel, Nicolaus & Company, Incorporated (Stifel) pursuant to which the Company may sell from time to time, at its option, up to an aggregate of $75.0 million of its shares of common stock through Stifel, as sales agent. Sales of the common stock made pursuant to the Sales Agreement, if any, will be made on the Nasdaq Global Select Market under the Companys previously filed and... More
Momenta (MNTA): Data Presented Supporting Sialylation Platform
May 2, 2014 8:50 AM EDTMomenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will present its approach to designing novel therapeutics by applying site-specific sialylation to Fc glycans in IVIg, monoclonal antibodies, and other recombinant Fc-containing proteins, in a presentation entitled "Embracing Complexity: Understanding IVIg to Rationally Engineer Novel Therapeutics". The presentation will be given by Tony... More
